Physician profile
Misty D Evans
NPI 1427470913
$22,081.74
in general payments reported to CMS, 2019-2025
44 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,120 · 2022: $3,283 · 2023: $1,035 · 2024: $2,246 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $3,428 · Travel and Lodging: $117 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,085.00 |
| Food and Beverage | $3,428.20 |
| Travel and Lodging | $117.34 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $9,498.79 | 2025 | Koselugo |
| Vertex Pharmaceuticals Incorporated | $4,611.74 | 2022-2025 | |
| Omeros Corporation | $2,500.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $2,386.13 | 2021-2025 | |
| Sobi, INC | $520.05 | 2022-2025 | |
| Novo Nordisk INC | $284.52 | 2021-2025 | Alhemo |
| Pfizer INC. | $199.87 | 2021-2025 | |
| Y-Mabs Therapeutics, INC. | $193.06 | 2021-2025 | Danyelza |
| Ucb, INC. | $169.58 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $150.41 | 2021-2025 | Livtencity, Eohilia, Elaprase |
| Agios Pharmaceuticals, INC. | $144.05 | 2022-2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $143.47 | 2023-2024 | |
| Csl Behring | $100.60 | 2021-2024 | Hemgenix, Idelvion |
| Amgen INC. | $89.14 | 2021-2022 | |
| Corium, LLC | $86.58 | 2024-2025 | Azstarys |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.